Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Net Cash Flow (2017 - 2025)

Historic Net Cash Flow for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to -$1.1 million.

  • Puma Biotechnology's Net Cash Flow fell 108771.93% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.7 million, marking a year-over-year increase of 875.17%. This contributed to the annual value of -$15.4 million for FY2024, which is 29490.11% down from last year.
  • According to the latest figures from Q3 2025, Puma Biotechnology's Net Cash Flow is -$1.1 million, which was down 108771.93% from -$8.4 million recorded in Q2 2025.
  • Over the past 5 years, Puma Biotechnology's Net Cash Flow peaked at $25.2 million during Q3 2022, and registered a low of -$25.9 million during Q3 2021.
  • Over the past 5 years, Puma Biotechnology's median Net Cash Flow value was -$1.8 million (recorded in 2022), while the average stood at -$2.2 million.
  • Per our database at Business Quant, Puma Biotechnology's Net Cash Flow tumbled by 307803.68% in 2021 and then skyrocketed by 22990.34% in 2023.
  • Quarter analysis of 5 years shows Puma Biotechnology's Net Cash Flow stood at -$816000.0 in 2021, then plummeted by 115.56% to -$1.8 million in 2022, then surged by 229.9% to $2.3 million in 2023, then decreased by 14.4% to $2.0 million in 2024, then crashed by 157.57% to -$1.1 million in 2025.
  • Its last three reported values are -$1.1 million in Q3 2025, -$8.4 million for Q2 2025, and -$6.2 million during Q1 2025.